AstraZeneca (LSE: AZN) and its research arm MedImmune, today announced the appointment of two internationally-recognized immuno-oncology leaders.
Dr Jean-Charles Soria joins MedImmune as senior vice president, head of oncology innovative medicines, and Dr Geoffrey Kim has been appointed as head of oncology strategic combinations at AstraZeneca.
{iframe}https://www.thepharmaletter.com/article/astrazeneca-adds-to-immuno-oncology-leadership-team{/iframe}